<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976052</url>
  </required_header>
  <id_info>
    <org_study_id>OSABiomarker</org_study_id>
    <nct_id>NCT01976052</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential Biomarkers for Obstructive Sleep Apnea and the Effect of Positive Pressure Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Potential biomarkers for obstructive sleep apnea (OSA), and full genomic screening will be
      evaluated and correlated to the degree of OSA and to effect of CPAP-treatment measured by
      polygraphy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Biomarker</measure>
    <time_frame>Comparison between 0, 3 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biomarkers related to inflammation, hypoxia, oxidative stress, redox and the central nervous system will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genomics</measure>
    <time_frame>Comparison between 0, 3, 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genomic screening by microarray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea hypopnea index</measure>
    <time_frame>Comparision between 0, 3 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apnea hypopnea index at 0, 3 and 12 month after treatment with CPAP in the obstructive sleep apnea groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>Comparision at 0, 3 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of exhaled nitric oxide</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Obstructive sleep apnea patients</arm_group_label>
    <description>Patients with obstructive sleep apnea that has not received CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched volunteers with non OSA</arm_group_label>
    <description>Matched volunteers without OSA. Matched in respect to age and BMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched normal controls with normal BMI</arm_group_label>
    <description>Volunteers that are matched according to age but has a normal BMI</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        OSA patients will be recruited from an outpatient sleep clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        OSA-patients with moderate and severe OSA (n=15+15)

          1. Adult, 18-75 years of age

          2. Moderate (AHI 15-30) or Severe (AHI &gt;30) OSA that are currently untreated and planned
             for CPAP-treatment

          3. Otherwise healthy except for well controlled hypertension since 3 month, Max BP
             140/90

          4. Non-smokers

          5. Not pregnant

          6. No medications with antioxidants

          7. BMI of &lt;40

        Controls (AHI&lt;5) Two groups of controls

          1. Matched controls The same age, sex and BMI Â± 3 and eventual hypertension. These
             controls should also fulfill criteria 4-6 above.

          2. Healthy controls with normal BMI (19-25) These controls should also fulfill criteria
             1., 4-6 above.

        Exclusion Criteria:

          -  If they no not fulfil the inclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malin Jonsson Fagerlund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital and Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malin Jonsson Fagerlund, MD, PhD</last_name>
    <phone>+46851772107</phone>
    <email>malin.jonsson.fagerlund@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology, Surgical Sciences and Intensive Care Medicine, Karolinska University Hospital, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Jonsson Fagerlund, MD, PhD</last_name>
      <phone>+46851772107</phone>
      <email>malin.jonsson.fagerlund@ki.se</email>
    </contact>
    <investigator>
      <last_name>Malin Jonsson Fagerlund, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Malin Jonsson Fagerlund</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Genomics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
